No Data
No Data
Maxim Group Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)
NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada
NeuroSense Therapeutics Shares Are Trading Higher After the Company Announced It Initiated a Process to Seek Early Commercialization Approval for PrimeC in ALS Under Heath Canada's Notice of Compliance With Conditions Policy.
Express News | Neurosense Therapeutics: Plans to Seek Approval in Additional Countries
Express News | Neurosense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
Express News | NeuroSense Therapeutics Announces Acceptance Of Two PrimeC Abstracts For ALS Treatment At 2024 NEALS Annual Meeting From Oct 21-24 In Clearwater, FL
No Data
No Data